Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.58 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.56 |
| ▸ | FXR2 | P51116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474127 | 0.95 | NR1H4 (0.58) | NR1H4HSD17B13FXR2 | |
| SCHEMBL23474113 | 0.94 | NR1H4 (0.60) | NR1H4HSD17B13FXR2 | |
| SCHEMBL30144872 | 0.94 | NR1H4 (0.60) | NR1H4HSD17B13FXR2 | |
| SCHEMBL23474176 | 0.93 | NR1H4 (0.59) | NR1H4HSD17B13FXR2 | |
| SCHEMBL23474149 | 0.92 | NR1H4 (0.51) | NR1H4HSD17B13 | |
| SCHEMBL32675680 | 0.91 | NR1H4 (0.61) | NR1H4HSD17B13FXR2 | |
| SCHEMBL23474097 | 0.91 | NR1H4 (0.61) | NR1H4HSD17B13FXR2 | |
| SCHEMBL23474096 | 0.90 | NR1H4 (0.69) | NR1H4HSD17B13FXR2 | |
| SCHEMBL25209031 | 0.89 | NR1H4 (0.68) | NR1H4HSD17B13FXR2 | |
| SCHEMBL23474114 | 0.89 | NR1H4 (0.61) | NR1H4HSD17B13FXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20220388997-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| WO-2021108974-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109712-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109713-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | NR1H4 116/4885HSD17B13 468/4885FXR2 661/4885 |
| US-20220388997-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | NR1H4, FXR1, FXR2 | NR1H4 1/4885HSD17B13 204/4885FXR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.